Biota, GSK Settle Relenza Marketing Suit For $19.5M

Law360, New York (July 22, 2008, 12:00 AM EDT) -- Australian drug firm Biota will receive $20 million Australian dollars ($19.46 million) from pharmaceutical giant GlaxoSmithKline over allegedly insufficient efforts to market the influenza drug Relenza.

The payout from GSK is about 3% of the maximum $704 million Australian ($685 million) it asked for when Biota first filed the lawsuit in 2004, and will only cover roughly half of the company's legal fees in litigating the case.

Biota sued GSK over four years ago over the limpid 1999 launch of its influenza vaccine, Relenza. The drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.